Unité Inserm U995, Service de Gastroentérologie, Hépatologie et Nutrition Pédiatrique, Pôle Enfant, Hôpital Jeanne de Flandre, CHRU de Lille, Avenue Eugène Avinée, 59037 Lille Cedex, France.
Eur J Pediatr. 2012 Dec;171(12):1767-73. doi: 10.1007/s00431-012-1807-4. Epub 2012 Aug 18.
This cross-sectional observational study aimed to determine the nationwide prevalence of gastroesophageal reflux disease (GORD) in French children and adolescents. Four hundred four general practitioners and 180 paediatricians compiled a register of all children and adolescents (n = 10,394, aged 0 to 17 years, mean 3.8 ± 5.6 years) who presented over two 3-day periods. For all children who, in the physician's opinion, showed symptoms of gastroesophageal reflux (GOR), a 24-item questionnaire covering the history and management of GOR was completed. Children with symptoms that impaired their daily lives were defined as having GORD, the remainder as having physiological GOR. Of the patients, 15.1 % showed GOR symptoms. Extrapolation to the overall French population yielded a prevalence of 10.3 % for GOR and 6.2 % for GORD. There was a significantly (p < 0.05) greater use of volume reduction or milk thickeners and dorsal positioning among infants with GORD versus physiological GOR. Significantly (p < 0.05) more of the infants and children with GORD received pharmacological therapy. The use of proton pump inhibitors increased with age but was significantly (p < 0.05) higher among those with GORD.
Ten percent of French children and adolescents show GOR symptoms and 6 % have GORD. Clinical presentation and treatment vary in different age groups, but those with GORD are more likely to require pharmacological treatment.
本横断面观察性研究旨在确定法国儿童和青少年胃食管反流病(GORD)的全国患病率。404 名全科医生和 180 名儿科医生对所有(n=10394 名,年龄 0 至 17 岁,平均 3.8±5.6 岁)在两个 3 天期间就诊的儿童和青少年进行了登记。对于所有在医生看来有胃食管反流(GOR)症状的儿童,均完成了一份涵盖 GOR 病史和管理的 24 项问卷。生活受到症状影响的儿童被定义为患有 GORD,其余为患有生理性 GOR。有 15.1%的患者出现 GOR 症状。推断法国总人口的患病率,GOR 为 10.3%,GORD 为 6.2%。与生理性 GOR 相比,患有 GORD 的婴儿更常使用体积减少或牛奶增稠剂和背部定位。患有 GORD 的婴儿和儿童更常接受药物治疗(p<0.05)。质子泵抑制剂的使用随着年龄的增长而增加,但 GORD 患者的使用显著(p<0.05)更高。
10%的法国儿童和青少年有 GOR 症状,6%有 GORD。临床表现和治疗在不同年龄组中有所不同,但 GORD 患者更有可能需要药物治疗。